Dr. Dong Ji: Exploring Liver Fibrosis Reversal and Personalized Treatment

Dr. Dong Ji: Exploring Liver Fibrosis Reversal and Personalized Treatment

The liver is a powerful organ with complex physiological structures and functions. Liver fibrosis is a dynamic pathological process associated with various chronic liver diseases, ultimately leading to cirrhosis. In cirrhosis, the liver not only becomes harder but also shrinks in size, with imaging showing changes in the liver's appearance accompanied by alterations in hepatic hemodynamics. Recently, at the 10th Beijing Hepatology Academic Annual Conference in 2024, Hepatology Digest invited Dr. Dong Ji from the Fifth Medical Center of the Chinese PLA General Hospital to discuss the latest insights and strategies on liver fibrosis reversal. The interview has been compiled into this article for readers to reference.
Dr. Hui Wang: PURPOSE 1 Study Reveals Outstanding Efficacy of Long-Acting Injectable Lenacapavir in Preventing HIV Infection in Women

Dr. Hui Wang: PURPOSE 1 Study Reveals Outstanding Efficacy of Long-Acting Injectable Lenacapavir in Preventing HIV Infection in Women

On July 24th, during the highly anticipated Co-Chairs' Choice session at the 25th International AIDS Conference in Munich, Germany, the PURPOSE 1 study was unveiled, highlighting a significant breakthrough in HIV prevention. The study demonstrated the exceptional efficacy of the long-acting injectable drug Lenacapavir in preventing HIV infection among women. The study was simultaneously published online in The New England Journal of Medicine. Conducted in South Africa and Uganda, this double-blind, randomized controlled trial compared different prevention strategies and found that biannual injections of Lenacapavir effectively blocked HIV infection, resulting in zero cases of infection. The efficacy of Lenacapavir far surpassed that of daily oral F/TAF and F/TDF. The study not only confirmed Lenacapavir's high effectiveness but also revealed its potential to improve patient adherence, offering a new solution to one of the major challenges in HIV prevention. With the widespread application of Lenacapavir, global HIV prevention strategies may be poised for significant change. Infectious Diseases Frontier invited Dr. Hui Wang from the Second Affiliated Hospital of Southern University of Science and Technology (Shenzhen Third People's Hospital) to provide an in-depth commentary and analysis of this study.
SIFIC 2024 | Dr. Fan Wu: Challenges and Control of Candida auris and Babesiosis

SIFIC 2024 | Dr. Fan Wu: Challenges and Control of Candida auris and Babesiosis

The 20th Shanghai International Forum for Infection Control (SIFIC) and the 8th Oriental Forum on Complex Infectious Diseases (OFCID), jointly held with the Global Chinese Society of Clinical Microbiology and Infectious Diseases (GCSCMID) Annual Meeting, successfully took place at the Shanghai International Convention Center from July 25-27, 2024. During the event, Dr. Fan Wu from Medical School of columbia University  delivered in-depth presentations on "Individual Diagnosis and Treatment of Candida auris Infections and Population-Level Prevention and Control" and "Mother-to-Child Transmission of Babesiosis - A Potentially Dangerous Blood Parasitic Disease." In an interview with "Infectious Diseases Frontier," Dr. Wu further elaborated on the global threat posed by Candida auris and the challenges in controlling Babesiosis, providing new insights and directions for the field of infection control.
News Express | Belzutifan, an Oral HIF-2α Inhibitor, for Treating VHL-Associated Congenital Polycythemia

News Express | Belzutifan, an Oral HIF-2α Inhibitor, for Treating VHL-Associated Congenital Polycythemia

The "News Express" column aims to bridge the gap between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to quickly grasp industry trends, spark innovative thinking, and broaden their professional horizons. Hematology News carefully curates the latest hematological research findings from top global journals. Each selected article represents a fusion of science and clinical practice, delivering the essence of hematology's advancements straight to you. Let knowledge transcend boundaries, and exploration never cease. We invite you to follow the column and join global hematology elites on a journey of scientific discovery! This issue features a case report from Haematologica on VHL-associated congenital polycythemia (CP).
Dr. Bing Xu: Understanding and Conquering IVLBCL—Progress in Diagnosis and Treatment | 2024 Northern Hematology and Oncology Immunotherapy Conference

Dr. Bing Xu: Understanding and Conquering IVLBCL—Progress in Diagnosis and Treatment | 2024 Northern Hematology and Oncology Immunotherapy Conference

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of non-Hodgkin lymphoma with atypical clinical presentations, leading to high rates of misdiagnosis and missed diagnosis in clinical practice. There is an urgent need to improve the current status of diagnosis and treatment. Recently, the "2024 Northern Hematology and Oncology Immunotherapy Conference," hosted by the Tianjin Society of Hematology and Regenerative Medicine, was held grandly in the northern coastal city of Tianjin. The conference brought together renowned hematology experts from across the country, focusing on the immunotherapy of hematologic malignancies. They explored the latest advances in the diagnosis and treatment of various hematologic sub-specialties, the pathogenesis of hematologic tumors, and progress in immunotherapy. At the conference, Dr. Bing Xu from The First Affiliated Hospital of Xiamen University delivered an outstanding report titled "Advances in the Diagnosis and Treatment of Intravascular Large B-Cell Lymphoma—Interpretation of the 2023 Chinese Expert Consensus," providing crucial guidance for comprehensively understanding and recognizing this disease. Hematology Frontier invited Dr. Bing Xu to share further insights on this topic.
Dr. Jun Shi: Ongoing Exploration to Optimize First-Line Treatment for Non-Gastric MALT Lymphoma | 2024 Northern Hematology and Oncology Immunotherapy

Dr. Jun Shi: Ongoing Exploration to Optimize First-Line Treatment for Non-Gastric MALT Lymphoma | 2024 Northern Hematology and Oncology Immunotherapy

While radiotherapy is the recommended first-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma, for certain non-gastric MALT lymphomas in specific locations, radiotherapy may result in significant side effects that can affect patients' quality of life. Recently, the "2024 Northern Hematology and Oncology Immunotherapy Conference," hosted by the Tianjin Society of Hematology and Regenerative Medicine, was held grandly in the northern coastal city of Tianjin. The conference brought together renowned hematology experts from across the country, focusing on the immunotherapy of hematologic malignancies. They explored the latest advances in the diagnosis and treatment of various hematologic sub-specialties, the pathogenesis of hematologic tumors, and progress in immunotherapy. At the conference, Dr. Jun Shi from Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, delivered an insightful presentation titled "Treatment Options for Localized Non-Gastric MALT Lymphoma," offering valuable guidance for optimizing the treatment of this disease. Hematology Frontier invited Dr. Jun Shi to further discuss this topic.
Dr. Sujun Zheng: From Hepatitis to Liver Cancer – Exploring Comprehensive Management of Liver Diseases

Dr. Sujun Zheng: From Hepatitis to Liver Cancer – Exploring Comprehensive Management of Liver Diseases

HBV infection is a major cause of chronic hepatitis B (CHB), cirrhosis, liver failure, and hepatocellular carcinoma. Despite the development of new drugs and advancements in antiviral therapy, a complete cure for CHB remains a clinical challenge. The burden of liver disease in China is still heavy, and the implementation of high-quality liver disease management is urgently needed. This involves a comprehensive approach that includes enhanced public education, convenient screening and monitoring, empowerment of primary healthcare, optimization of doctor incentives, refined data management, and scientifically sound prevention and treatment strategies. Recently, Dr. Sujun Zheng from Beijing You An Hospital, Capital Medical University, provided a systematic overview of the exploration and progress in comprehensive liver disease management during an academic exchange. The following is a summary of the key points shared.
Voice of China in AIDS Research丨Dr. Fujie Zhang’s Team: Efficacy of Long-term Antiretroviral Therapy in Chinese Children and Adolescents with HIV

Voice of China in AIDS Research丨Dr. Fujie Zhang’s Team: Efficacy of Long-term Antiretroviral Therapy in Chinese Children and Adolescents with HIV

From July 22-26, 2024, the 25th International AIDS Conference took place in Munich, Germany, gathering 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in AIDS prevention and treatment. At the conference, Dr. Hanxi Zhang from Dr. Fujie Zhang’s team at Beijing Ditan Hospital presented a multicenter, prospective, longitudinal cohort study conducted in China, which garnered widespread attention. Led by Beijing Ditan Hospital, Capital Medical University, this study aimed to evaluate the impact of antiretroviral therapy (ART) on mortality and virologic response in children and adolescents with HIV. The findings provided valuable insights into the long-term efficacy of ART in Chinese children living with HIV, indicating significant achievements of the ART program in this demographic. We invited Dr. Fujie Zhang to offer an in-depth analysis of the study's findings.
2024 CUDA丨Dr. Xiongjun Ye: Mastering the Characteristics and Approaches of Robot-Assisted Partial Nephrectomy, Clarifying the Path to Optimization

2024 CUDA丨Dr. Xiongjun Ye: Mastering the Characteristics and Approaches of Robot-Assisted Partial Nephrectomy, Clarifying the Path to Optimization

From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. Organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology Physicians Branch of the Shaanxi Medical Doctor Association, the conference showcased the latest achievements in urology from a broad and multidimensional perspective under the theme "Healthy China, Urology Leads the Way." At the conference, Urology Frontier interviewed Dr. Xiongjun Ye from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, who shared insights on the advantages of partial nephrectomy, discussed the approaches for robot-assisted partial nephrectomy, and explored the optimization directions for this surgical technique, offering valuable clinical guidance.